99mTc-fanolesomab Palatin Technologies.
99mTc-fanolesomab is a radiolabeled imaging agent which is being developed by Palatin Technologies for use in the diagnosis of various infections, including appendicitis and osteomyelitis.
Love
Charito
C
Long Island Jewish Medical Center, Division of Nuclear Medicine, 270-05 76th Avenue, New Hyde Park, NY 11040, USA.
Palestro
Christopher J
CJ
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D006801:Humans; D007239:Infections / Q000175:diagnosis; D007275:Injections, Intravenous; D016256:Lewis X Antigen / Q000378:metabolism; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000493:pharmacokinetics; D013329:Structure-Activity Relationship; D013667:Technetium
D000911:Antibodies, Monoclonal; D016256:Lewis X Antigen; D019275:Radiopharmaceuticals; D013667:Technetium; C414128:techneticum TC-99M fanolesomab